Dimensional Fund Advisors LP Has $135.08 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Dimensional Fund Advisors LP lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 64.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 494,604 shares of the medical research company’s stock after buying an additional 193,700 shares during the period. Dimensional Fund Advisors LP owned about 1.73% of Bio-Rad Laboratories worth $135,081,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Capital Advisors Ltd. LLC lifted its stake in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after acquiring an additional 62 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in shares of Bio-Rad Laboratories in the first quarter worth approximately $38,000. Principal Securities Inc. acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth approximately $41,000. EntryPoint Capital LLC purchased a new position in Bio-Rad Laboratories during the first quarter valued at approximately $51,000. Finally, Headlands Technologies LLC acquired a new position in Bio-Rad Laboratories in the 2nd quarter valued at approximately $51,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Insider Buying and Selling

In related news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP James Barry sold 623 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at approximately $2,494,016.46. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Bio-Rad Laboratories Stock Performance

BIO opened at $330.01 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. The company has a market cap of $9.41 billion, a PE ratio of -31.85 and a beta of 0.95. The stock has a 50-day moving average of $323.76 and a 200-day moving average of $307.68. Bio-Rad Laboratories, Inc. has a 52-week low of $261.59 and a 52-week high of $366.30.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The firm had revenue of $638.50 million during the quarter, compared to analysts’ expectations of $645.79 million. During the same quarter in the prior year, the business earned $3.00 earnings per share. The company’s revenue was down 6.3% on a year-over-year basis. As a group, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on BIO shares. Citigroup boosted their price target on shares of Bio-Rad Laboratories from $300.00 to $350.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $401.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Jefferies Financial Group reissued a “hold” rating and issued a $315.00 price target (down previously from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday, June 3rd. Finally, Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective on the stock. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $358.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.